Pharming Group N.V.

PHARM

NL0010391025

Pharmaceuticals

Market Closed - Euronext Amsterdam Other stock markets 11:35:09 2024-06-14 am EDT			5-day change	1st Jan Change
0.743 ^EUR	-1.00%		-5.95%	-27.93%

May. 31	Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug	MT
May. 30	Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union	CI

Pharming N : Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

May 22, 2024 at 04:06 am EDT

Pharming Group N.V.

Pharming Group N.V.

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date21 may 2024 - 17:32

Statutory namePharming Group N.V.

TitlePharming Group reports on results of the 2024 Annual General Meeting of Shareholders

Previous result

Next result

Related downloads

202405210000000012_Pharming AGM 2024 Press Release_EN_21MAY24.pdf(opens in a new window)

202405210000000012_Pharming AGM 2024 Press Release_NL_21MAY24.pdf(opens in a new window)

Date last update: 22 May 2024

Attachments

Original Link
Permalink

Disclaimer

Pharming Group NV published this content on 21 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 May 2024 08:05:04 UTC.

Latest news about Pharming Group N.V.

Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug	May. 31	MT
Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union	May. 30	CI
Transcript : Pharming Group N.V. - Shareholder/Analyst Call	May. 21
Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024	May. 08
Pharming Group N.V. Provides Revenue Guidance for 2024	May. 08	CI
Pharming Group N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Pharming Group to Buy Back EUR123 Million of Bonds due 2025	Apr. 22	MT
Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds	Apr. 18	MT
Pharming Group N.V. announced that it expects to receive ?100 million in funding	Apr. 17	CI
Pharming Group N.V. Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib	Apr. 08	CI
Pharming Group Finishes Enrolling Patients for Phase 3 Pediatric Testing of its Treatment for Rare Auto-Immune Disorder	Apr. 08	MT
Pharming Group N.V. Provides Earnings Guidance for the Year 2024	Mar. 14	CI
Pharming Group Seeks Acquisitions	Mar. 14	CI
Transcript : Pharming Group N.V., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
Pharming Group N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Pharming Group N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
RBC Raises Price Target on Pharming Group to EUR2.10 From EUR1.95, Keeps Outperform Rating	Jan. 09	MT
Pharming Group Announces Development Plans for Leniolisib for Additional Primary Immunodeficiencies	Dec. 15	CI
Pharming Group Plans Phase 2 Trial for Immune System Drug in 2024	Dec. 13	MT
Pharming Group Plans to Develop Leniolisib for Additional Primary Immunodeficiencies Following Engagement With FDA	Dec. 13	MT
Pharming Group Expects EU Panel Opinion in 2024 for Rare Immunodeficiency Treatment	Nov. 10	MT
Transcript : Pharming Group N.V., Q3 2023 Earnings Call, Oct 26, 2023	23-10-26
Pharming Group N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Pharming Group N.V. Appoints Richard Peters as Non-Executive Director	23-09-25	CI
Transcript : Pharming Group N.V. - Shareholder/Analyst Call	23-09-25

Chart Pharming Group N.V.

Duration

Period

More charts

Company Profile

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.

Sector

Pharmaceuticals

Calendar

2024-06-24 - Oppenheimer Novel Targets in Immunology Summit

More about the company

Income Statement Evolution

More financial data

Ratings for Pharming Group N.V.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.743 EUR

Average target price

1.875 EUR

Spread / Average Target

+152.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMING GROUP N.V.	-27.93%	535M
ELI LILLY AND COMPANY	+50.70%	791B
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B

Other Pharmaceuticals

Pharming Group N.V.

Equities

PHARM

NL0010391025

Pharmaceuticals

Pharming N : Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

EPS Revisions